Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
0.870
+0.111 (14.62%)
At close: Nov 22, 2024, 4:00 PM
1.090
+0.220 (25.29%)
After-hours: Nov 22, 2024, 7:59 PM EST
Biofrontera Employees
As of December 31, 2023, Biofrontera had 85 total employees, including 83 full-time and 2 part-time employees. The number of employees increased by 4 or 4.94% compared to the previous year.
Employees
85
Change (1Y)
4
Growth (1Y)
4.94%
Revenue / Employee
$415,976
Profits / Employee
-$151,024
Market Cap
4.82M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85 | 4 | 4.94% |
Dec 31, 2022 | 81 | 12 | 17.39% |
Dec 31, 2021 | 69 | 13 | 23.21% |
Dec 31, 2020 | 56 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Check-Cap | 85 |
Biomerica | 64 |
Sunshine Biopharma | 44 |
Aptose Biosciences | 36 |
Predictive Oncology | 35 |
Purple Biotech | 20 |
Portage Biotech | 7 |
Creative Medical Technology Holdings | 4 |
BFRI News
- 19 hours ago - Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewsWire
- 8 days ago - Biofrontera Inc. (BFRI) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 21 days ago - Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Accesswire
- 22 days ago - Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - GlobeNewsWire
- 6 weeks ago - FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - GlobeNewsWire
- 2 months ago - Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - Accesswire